A Phase 1 interventional study of GDC-0973 IV Infusion and GDC-0973 Oral Capsules in Healthy Volunteers, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973. The primary objectives of Part 2 of this study are to evaluate the absolute bioavailability of GDC-0973 and to evaluate the pharmacokinetic (PK) of GDC-0973 following IV and oral administration. The secondary objective of Part 2 of this study is to evaluate the safety of GDC-0973 administered orally and intravenously.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules
Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules
Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
Drug: GDC-0973 IV Infusion · Drug: GDC-0973 Oral Capsules
IV infusion.
Also known as: XL518
Oral dose.
Also known as: XL518
Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973
Time frame: Part 2: 0 hours (Hrs) (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Dose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-0973
Cmax(dn) is Cmax divided by dose.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Minimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-0973
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Time to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-0973
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Dose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-0973
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). AUC (0-t)dn is AUC (0-t) divided by dose.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973
AUC (0 - ∞)= Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Dose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-0973
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞)dn is AUC(0 - ∞) divided by dose.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Plasma Decay Half-Life (t1/2) of IV and Oral GDC-0973
t1/2 is the time measured for the plasma concentration of GDC-0973 to decrease by one half.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Systemic Clearance (CL) of IV GDC-0973
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Apparent Oral Clearance (CL/F) of Oral GDC-0973
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modelling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Volume of Distribution at Steady State (Vss) of IV GDC-0973
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vss is the apparent volume of distribution at steady-state.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose of Day 1
Apparent Volume of Distribution (Vz/F) of Oral GDC-0973
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Absolute Oral Bioavailability (F) of GDC-0973
Absolute oral bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose. F = \[AUC (0-∞), oral multiplied by Dose IV\] divided by \[AUC (0-∞), IV multiplied by Dose oral\]. Absolute oral bioavailability is determined for drugs which are administered orally. IV dose is 100% in systemic circulation (dosed directly) and hence no estimation is required.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Mean Absorption Time (MAT)
MAT is mean time required for the drug to reach the central compartment. MAT was estimated from the mean resident time (MRT) from oral and IV administration. MAT was calculated as MRT last of oral dose minus MRT last of IV dose. MAT is analyzed when drug is administered orally (only for non-IV routes of administration).
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1
Amount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-0973
The cumulative amount of drug excreted in urine over the entire collection interval of 96 hrs was calculated by adding the Aeu of the intervals 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 hrs where Aeu was calculated by multiplying the urine volume within the collection interval by the associated drug concentration.
Time frame: Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose on Day 1
Renal Clearance (CLR) of IV and Oral GDC-0973
CLR was calculated as Aeu divided by AUC (0 - ∞), where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose and AUC(0 - ∞) was area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity hrs post-dose.
Time frame: Part 2: 0 Hrs (pre-dose), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 Hrs post-dose on Day 1 for plasma; 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose for urine
Percent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-0973
% Excreted is the mean percentage of dose recovery in urine and calculated as: (Aeu divided by dose) multiplied by 100, where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose.
Time frame: Part 2: 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 Hrs post-dose
| Milestone | Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion |
|---|---|---|---|
| Started | 2 | 6 | 5 |
| Completed | 2 | 6 | 5 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion |
|---|---|---|---|
| Started | 2 | 6 | 5 |
| Completed | 2 | 5 | 5 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Milestone | Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion |
|---|---|---|---|
| Started | 2 | 5 | 5 |
| Completed | 2 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules | Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion |
|---|---|---|---|
| Started | 2 | 5 | 5 |
| Completed | 2 | 5 | 5 |
| Not completed | 0 | 0 | 0 |
| nanograms per milliliter (ng/mL) | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of IV and Oral GDC-0973 | 20.5 ± 35.6 | 15.2 ± 26.4 |
Cmax(dn) is Cmax divided by dose.
| ng/mL/mg | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Dose Normalized Cmax [Cmax(dn)] of IV and Oral GDC-0973 | 10.2 ± 35.6 | 0.844 ± 26.4 |
| ng/mL | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Minimum Observed Plasma Trough Concentration (Cmin) of IV and Oral GDC-0973 | 0.261 ± 37.1 | 0.546 ± 70.0 |
| hr | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of IV and Oral GDC-0973 | 0.500 (0.500 to 0.567) | 4.00 (2.00 to 8.00) |
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).
| ng*hr/mL | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of IV and Oral GDC-0973 | 156 ± 19.1 | 688 ± 28.4 |
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t). AUC (0-t)dn is AUC (0-t) divided by dose.
| ng*hr/mL/mg | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Dose Normalized AUC (0-t) [AUC (0-t)dn] of IV and Oral GDC-0973 | 77.8 ± 19.1 | 38.2 ± 28.4 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of IV and Oral GDC-0973 | 188 ± 16.2 | 784 ± 29.5 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞)dn is AUC(0 - ∞) divided by dose.
| ng*hr/mL/mg | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Dose Normalized AUC (0 - ∞) [AUC (0 - ∞)dn] of IV and Oral GDC-0973 | 93.9 ± 16.2 | 43.5 ± 29.5 |
t1/2 is the time measured for the plasma concentration of GDC-0973 to decrease by one half.
| hr | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Plasma Decay Half-Life (t1/2) of IV and Oral GDC-0973 | 73.8 ± 17.1 | 66.2 ± 18.2 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
| Liter (L)/hr | GDC-0973 2 mg IV |
|---|---|
| Systemic Clearance (CL) of IV GDC-0973 | 10.7 ± 16.2 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modelling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | GDC-0973 20 mg Oral |
|---|---|
| Apparent Oral Clearance (CL/F) of Oral GDC-0973 | 23.0 ± 29.5 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vss is the apparent volume of distribution at steady-state.
| Liter | GDC-0973 2 mg IV |
|---|---|
| Volume of Distribution at Steady State (Vss) of IV GDC-0973 | 1052 ± 28.2 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F is influenced by the fraction absorbed.
| Liter | GDC-0973 20 mg Oral |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Oral GDC-0973 | 2197 ± 31.9 |
Absolute oral bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose. F = \[AUC (0-∞), oral multiplied by Dose IV\] divided by \[AUC (0-∞), IV multiplied by Dose oral\]. Absolute oral bioavailability is determined for drugs which are administered orally. IV dose is 100% in systemic circulation (dosed directly) and hence no estimation is required.
| Ratio | GDC-0973 20 mg Oral |
|---|---|
| Absolute Oral Bioavailability (F) of GDC-0973 | 0.457 ± 25.0 |
MAT is mean time required for the drug to reach the central compartment. MAT was estimated from the mean resident time (MRT) from oral and IV administration. MAT was calculated as MRT last of oral dose minus MRT last of IV dose. MAT is analyzed when drug is administered orally (only for non-IV routes of administration).
| hr | GDC-0973 20 mg Oral |
|---|---|
| Mean Absorption Time (MAT) | 2.67 ± 58.0 |
The cumulative amount of drug excreted in urine over the entire collection interval of 96 hrs was calculated by adding the Aeu of the intervals 0 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 hrs where Aeu was calculated by multiplying the urine volume within the collection interval by the associated drug concentration.
| mg | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Amount of Drug Excreted in the Urine (Aeu) of IV and Oral GDC-0973 | 0.0761 ± 22.3 | 0.379 ± 33.9 |
CLR was calculated as Aeu divided by AUC (0 - ∞), where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose and AUC(0 - ∞) was area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity hrs post-dose.
| L/hr | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Renal Clearance (CLR) of IV and Oral GDC-0973 | 0.405 ± 20.1 | 0.484 ± 22.4 |
% Excreted is the mean percentage of dose recovery in urine and calculated as: (Aeu divided by dose) multiplied by 100, where Aeu was amount of drug excreted in urine from time 0 to 96 hrs post-dose.
| Percent dose excreted | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| Percent of GDC-0973 Excreted in the Urine (% Excreted) for IV and Oral GDC-0973 | 3.81 ± 22.3 | 1.90 ± 33.9 |
Collected over Adverse events were recorded from start of study treatment in first period to end of second period (up to 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GDC-0973 2 mg IV | — | 0/13 (0%) | 2/13 (15.4%) |
| GDC-0973 20 mg Oral | — | 0/12 (0%) | 3/12 (25%) |
| Event | GDC-0973 2 mg IV | GDC-0973 20 mg Oral |
|---|---|---|
| NauseaGastrointestinal disorders | 0/13 | 2/12 |
| DizzinessNervous system disorders | 0/13 | 2/12 |
| VomitingGastrointestinal disorders | 0/13 | 1/12 |
| HeadacheNervous system disorders | 1/13 | 1/12 |
| Loss of consciousnessNervous system disorders | 0/13 | 1/12 |
| Feeling hotGeneral disorders | 0/13 | 1/12 |
| ExcoriationInjury, poisoning and procedural complications | 0/13 | 1/12 |
| Skin lacerationInjury, poisoning and procedural complications | 0/13 | 1/12 |
| Neck painMusculoskeletal and connective tissue disorders | 0/13 | 1/12 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/13 | 1/12 |
Safety population included participants who received study drug and had at least 1 post-dose safety assessment for Part 1 and the participants who were randomized, received study drug, and had at least 1 post-dose safety assessment for Part 2.
| Age, Continuous(Years) | Entire Study Population |
|---|---|
| Mean | 35 ± 10.2 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 5 |
| Male | 8 |
No study locations are listed for this record.
The record gives a start of Nov 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 6 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cobimetinib